Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Marciniak

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Cardiology|September 13, 2017
Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS)Victor L Serebruany, Vasily Cherepanov, Moo Hyun Kim, et al.
International Journal of Cardiology|April 30, 2016
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trialVictor L Serebruany, Moo Hyun Kim, Elena Golukhova, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 23, 2017
Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting SystemVasily Cherepanov, Seth D Fortmann, Moo Hyun Kim, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 8, 2018
Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting SystemVictor L Serebruany, Trygve S Hall, Dan Atar, et al.
Thrombosis and Haemostasis|February 19, 2016
Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulationVictor L Serebruany, Seth D Fortmann, Sunil V Rao, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Cardiology|September 13, 2017
Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS)Victor L Serebruany, Vasily Cherepanov, Moo Hyun Kim, et al.
International Journal of Cardiology|April 30, 2016
Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trialVictor L Serebruany, Moo Hyun Kim, Elena Golukhova, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 23, 2017
Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting SystemVasily Cherepanov, Seth D Fortmann, Moo Hyun Kim, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 8, 2018
Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting SystemVictor L Serebruany, Trygve S Hall, Dan Atar, et al.
Thrombosis and Haemostasis|February 19, 2016
Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulationVictor L Serebruany, Seth D Fortmann, Sunil V Rao, et al.
Pageof 3